A5083944894- Psoriasis: Treatment and Pathogenesis
- Health Systems, Economic Evaluations, Quality of Life
- Dermatology and Skin Diseases
- Pharmaceutical studies and practices
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Drug-Induced Adverse Reactions
- Complementary and Alternative Medicine Studies
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Heparin-Induced Thrombocytopenia and Thrombosis
- Asthma and respiratory diseases
Guy's and St Thomas' NHS Foundation Trust
2021-2025
National Health Service
2023
King's College London
2020-2023
Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses BNT162b2 (Pfizer-BioNTech) in patients taking methotrexate commonly used targeted biological therapies, compared with healthy controls. Given the roll-out of extended interval vaccination programmes maximise population coverage, we present findings after first dose.In this cohort study, recruited...
BackgroundCOVID-19 vaccines have robust immunogenicity in the general population. However, data for individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains scarce. Our previously published cohort study showed that methotrexate, but not targeted biologics, impaired functional humoral immunity to a single dose of COVID-19 vaccine BNT162b2 (Pfizer-BioNTech), whereas cellular responses were similar. Here, we aimed assess immune following second...
Rising numbers of individuals receiving psoriasis biologics achieve clear/nearly clear skin (disease control). Trial data indicate some maintain control with lower doses, especially those higher serum drug concentrations. This indicates potential for Model-Informed Precision Dosing (MIPD), an advanced therapeutic monitoring technique, in guiding dose minimisation. We developed, validated, and user-tested a precision dosing dashboard. applied MIPD approach leveraging Bayesian estimation to...
<h3>Importance</h3> The emerging paradigm of treat-to-target in psoriasis requires accurate monitoring treatment response. commonly used physician global assessment tool does not capture the patient's perception their disease. Patient assessments facilitate shared decision-making and foster patient-centered care; however, recent research reports a discordance between patient- physician-reported severity. Understanding factors underlying this may improve satisfaction disease outcomes....
Although palmoplantar pustulosis (PPP) can significantly impact quality of life, the factors underlying disease severity have not been studied.To examine associated with PPP severity.An observational, cross-sectional study 2 cohorts was conducted. A UK data set including 203 patients obtained through Anakinra in Pustular Psoriasis, Response a Controlled Trial (2016-2019) and its sister research Elucidating Underlying Mechanisms (2016-2020). Northern European cohort 193 independently...
Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), important cause treatment failure. The most widely used across immune-mediated diseases is adalimumab, a tumor necrosis factor inhibitor. This study aimed to identify genetic variants that contribute ADA against thereby influencing In patients with psoriasis on their first course in whom serum had been evaluated 6-36 months after starting treatment, we...
Serum adalimumab concentration is a biomarker of treatment response but therapeutic drug monitoring (TDM) yet to be implemented in routine psoriasis care. We incorporated TDM national specialized service and evaluated it using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) implementation science framework. undertook pre-implementation planning (validating local assays) interventions targeted patients (pragmatic sampling at reviews), clinicians (introduction...